Valuation: Prothena Corporation plc

Market Cap 458M 402M 374M 343M 645M 44.11B 655M 4.44B 1.74B 21.69B 1.72B 1.68B 74.99B P/E 2026 *
187x
P/E 2027 * -8.5x
Enterprise Value 458M 402M 374M 343M 645M 44.11B 655M 4.44B 1.74B 21.69B 1.72B 1.68B 74.99B EV / Sales 2026 *
5.5x
EV / Sales 2027 * 20.8x
Free-Float
79.82%
Yield 2026 *
-
Yield 2027 * -
1 day+2.58%
1 week+1.04%
Current month-10.62%
1 month-6.91%
3 months-18.60%
6 months-12.50%
Current year-8.38%
1 week 8.23
Extreme 8.23
8.85
1 month 8.08
Extreme 8.075
10.15
Current year 7.73
Extreme 7.73
11.8
1 year 6.61
Extreme 6.61
11.8
3 years 4.32
Extreme 4.32
70.09
5 years 4.32
Extreme 4.32
79.75
10 years 4.32
Extreme 4.32
79.75
Manager TitleAgeSince
Chief Executive Officer 57 30/09/2016
Director of Finance/CFO 52 01/04/2013
Chief Operating Officer 52 29/09/2021
Director TitleAgeSince
Chairman 76 20/12/2012
Director/Board Member 72 20/12/2012
Director/Board Member 63 20/12/2012
Date Insider Type Main position Quantity % Market Cap.
16/06/26 Buy 20,000 0.0382%
15/06/26 Don -325,000 0.6208%
11/06/26 Buy 125,000 0.2388%
Change 5-day change 1-year change 3-year change Capi.($)
+2.58%+1.04%+30.60%-86.49% 458M
+0.93%+6.97%+62.83%+67.97% 57.28B
-1.92%+6.03%+43.68%+84.56% 54.99B
-0.46%-1.29%+3.28%+422.58% 23.18B
-2.97%-2.35%-22.03%-16.54% 22.59B
-0.36%+5.73%+30.99%-3.58% 20.46B
-1.34%+0.51%+25.02%-30.27% 17.56B
-1.44%+5.67%+32.54%+544.11% 15.67B
-1.30%-5.02%+165.62%+291.37% 14.46B
-0.50%-0.98%+23.62%+178.38% 13.92B
Average -0.68%+1.25%+39.62%+145.21% 24.06B
Weighted average by Cap. -0.87%+2.09%+41.16%+135.26%

Financials

2026 *2027 *
Net sales 83.32M 73.18M 68.06M 62.45M 117M 8.02B 119M 808M 316M 3.94B 313M 306M 13.64B 22M 19.32M 17.97M 16.49M 30.98M 2.12B 31.46M 213M 83.37M 1.04B 82.59M 80.81M 3.6B
Net income 2.42M 2.13M 1.98M 1.82M 3.41M 233M 3.47M 23.5M 9.18M 115M 9.1M 8.9M 397M -55.93M -49.12M -45.68M -41.92M -78.76M -5.39B -79.98M -542M -212M -2.65B -210M -205M -9.16B
Net Debt - -
Logo Prothena Corporation plc
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Employees
67
Date Price Change Volume
24/07/26 $8.750 +2.58% 576,837
23/07/26 $8.530 +1.07% 532,213
22/07/26 $8.440 -3.54% 542,549
21/07/26 $8.750 +0.92% 647,644
20/07/26 $8.670 +0.12% 549,625
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
8.750USD
Average target price
21.40USD
Spread / Average Target
+144.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRTA Stock